Illinois Tool Works Inc. (NYSE: ITW) — The Gold Standard of Industrial Compounding, Priced for Its Quality but Not Its Growth

⚡ Claude’s Take

This block is the author’s own independent opinion and general information only — it is not investment advice. The analysis that follows takes no position and carries no price target.

Verdict: HOLD / own-for-the-quality / accumulate-on-weakness toward ~$230–250 (≈20–21x forward EPS). Not-a-short. Directional fair-value zone ~$240–290. Conviction: medium.

Illinois Tool Works is, by the numbers, the single highest-quality diversified industrial in my coverage universe — and the cleanest. A ~27% return on invested capital and ~26% operating margins, earned on a largely organic capital base rather than a goodwill pile, are the financial fingerprints of a real, durable moat (Greenwald: customer-captivity switching costs + patented intangibles at niche scale, amplified by the 80/20 operating system). The balance sheet is a fortress, capital allocation is genuinely best-in-class (returns-aligned long-term comp that actually includes ROIC, a 62-year dividend-increase streak, disciplined valuation-gated M&A, steady buybacks), and the accounting is conservative with near-zero stock-comp dilution. None of that is the debate.

The debate is growth and price. Revenue has plateaued at ~$16B for four years; organic growth has run near zero through a CapEx/short-cycle trough, FX, and deliberate product-line pruning. The market pays ~23x forward earnings and ~18x EV/EBITDA — the 85th percentile of ITW’s own decade-long valuation range — for a company whose EPS growth has lately come more from margin initiatives and buybacks than from volume. That is a quality-compounder-at-a-full-price setup, not a bargain and not a bubble: the factor tape confirms it — low beta (0.71), positive Value/Quality/DividendYield loadings, negative Growth and Momentum, an abandoned-defensive profile, not a melt-up and not a falling knife. You are paying a fair-to-full multiple for certainty of returns, with the upside optionality being a genuine organic-growth re-acceleration (Customer-Back Innovation reaching scale + the early-2026 inflection in Welding and semis). I would happily own ITW for its quality and its compounding, but I want a slightly better entry than today’s ~$264 to build in a margin of safety against the one thing it has not proven this decade: that it can grow the top line again.

What would flip me bullish: two-to-three quarters of sustained 4%+ organic growth (CBI yield through ~3% + cyclical recovery), confirming the franchise compounds on volume again — at which point ~23x is cheap. What would flip me bearish: organic growth re-stalling toward zero with the multiple still ≥23x, i.e., paying a growth price for a no-growth annuity. Tag: the gold standard of industrial compounding — you’re paying for the quality, not getting the growth for free.

📈 Stock Price Action — Five-Year Event Map

ITW is a low-drama compounder, and the chart shows it. Over the trailing five years the stock roughly doubled off its 2022 low (~$161 split/dividend-adjusted) to an all-time high of ~$298 on 2026-02-13, and now trades at $264.09 (2026-06-18), about −11% off that high. The 52-week range is ~$235–298. The maximum drawdown was the orderly 2022 rate-shock pullback; there has been no crash, no blow-up — just a grind higher punctuated by macro air-pockets. Beta is 0.71 and idiosyncratic volatility is low (~12% annualized), consistent with a defensive blue-chip whose price is driven more by rates and the industrial cycle than by company-specific news.

Cycle narrative. (1) ITW entered 2021 on the post-COVID volume rebound but its already-premium multiple limited the re-rate. (2) The 2022 bear market and rate shock produced the period’s only real drawdown — a market-multiple event, not a fundamental one. (3) From the 2022 low, the stock compounded back to new highs powered by ITW’s signature self-help margin expansion and through-cycle pricing power, not by volume. (4) 2024 was dead-money: the optically strong FY24 EPS ($11.75) was flattered by ~$1.56 of one-time items (the Wilsonart divestiture gain + a LIFO accounting change), masking a flat underlying year as organic growth stalled. (5) Early 2026 delivered the move to an all-time high on a constructive FY26 guide, the first organic inflection in the CapEx-exposed segments (semis, Welding) in three years, and FX flipping from headwind to tailwind. (6) The subsequent ~11% pullback is unremarkable profit-taking on a quiet tape — no negative catalyst. (Price moves are FACT from the AZI five-year series; attributed drivers are INTERPRETATION cross-referenced to earnings dates, guidance, and 8-K events.)

1. Executive Summary

Illinois Tool Works is a $16B-revenue, ~$76B-market-cap diversified industrial manufacturer operating seven balanced segments (Automotive OEM, Food Equipment, Test & Measurement and Electronics, Welding, Polymers & Fluids, Construction Products, Specialty Products) through a federation of ~80–90 decentralized businesses unified by the proprietary “ITW Business Model” (80/20 Front-to-Back, Customer-Back Innovation, decentralized culture). It is, on the evidence, the best and cleanest compounder in the diversified-industrial cohort: ~27% ROIC, ~26% operating margins, ~44% gross margins, light capex (~2.6% of sales), negligible stock comp (~0.4% of sales), and a 62-year consecutive dividend-increase record.

The moat is real and durable. ITW sells engineered, often patent-protected components and consumables (a ~21,800-patent portfolio) that are a small fraction of a customer’s cost but critical to product/process performance — generating switching costs and pricing power disproportionate to the dollars supplied. The decisive evidence is that ITW’s ~27% ROIC is earned on a largely organic capital base, whereas peers (EMR ~10%, PH ~16%, HON ~17%, AME ~12% on deployed capital) show strong underlying returns diluted to mediocrity by goodwill-heavy M&A. ITW’s consolidated ROIC is its elite tangible ROIC. Welding’s stable global oligopoly (vs. Lincoln Electric and ESAB) and through-cycle pricing across a four-year revenue plateau corroborate stable share.

The bear case is not the moat — it is growth and valuation. Revenue has been flat at ~$16B since FY22; organic growth has run near zero through a CapEx-cycle trough, multi-year FX drag, and deliberate product-line simplification. EPS growth has leaned on ~100 bps/year of self-funded margin expansion plus ~2 pts/year of buyback rather than volume. The stock trades at ~23x forward EPS, ~18x EV/EBITDA, and a ~3.5% FCF yield — the 85th percentile of its own decade-long valuation range. The market is paying a premium-quality multiple, and the embedded expectation is continuation of ~7–8% EPS growth with the multiple intact. That is reasonable for this franchise but offers little margin of safety against a re-stall in organic growth.

The forward call hinges on one observable question: can Customer-Back Innovation (2.4% of revenue in FY25, targeting 3%+) plus the early-2026 cyclical recovery in semis (+15% organic in Q1-26) and Welding (+6%) re-establish 4%+ organic growth? Early evidence is encouraging but unproven. This is a high-quality, defensively-positioned compounder fully priced for its quality and not discounting much growth — own it for the returns and the dividend; demand a better entry for a margin of safety. No recommendation or price target appears below; valuation is treated as embedded expectations and scenarios.

2. Business Overview

Illinois Tool Works is a diversified, multi-industry manufacturer operating through seven reportable segments across 49 countries (FACT, FY25 10-K, Item 1). The structural distinction from the conglomerate model (the old GE, Honeywell) is that ITW is not a collection of standalone divisions but a federation of ~80–90 highly decentralized businesses run on a single proprietary operating system. It makes money by selling engineered, proprietary, frequently patent-protected components and consumables that represent a small fraction of a customer’s total cost but are critical to that customer’s product performance or production process — then layering recurring aftermarket service, consumables, and replacement parts on top of the installed base.

The seven segments (FY25). Revenue, segment operating income, and computed margin (FACT, FY25 10-K segment results):

The portfolio is remarkably balanced: the largest segment (Auto OEM) is only ~20% of revenue and the smallest ~11%, so no single end market can sink the enterprise. Welding (32.9%), Specialty (31.2%) and Construction (30.2%) lead on margin; Auto OEM (21.1%) is the structural laggard, reflecting a powerful, consolidated customer base.

Geographic mix (FACT, FY25 10-K, customer-location basis): North America $8,480M (53%; US alone ~46%), EMEA $4,162M (26%), Asia-Pacific $3,079M (19%), South America $323M (2%) — roughly 47% international, diversified but US-centric.

Revenue model and recurrence. ITW does not disclose a clean recurring-revenue percentage, but by construction a large share is consumable/aftermarket rather than capital-equipment: Welding sells equipment and recurring consumables; Food Equipment carries a dedicated service/maintenance business; Polymers & Fluids and Specialty are largely consumables; Test & Measurement carries consumables and MRO (INTERPRETATION). This annuity-like tail is the structural buffer that held enterprise margins at ~26–27% through a four-year revenue plateau — the franchise is more recurring than its “industrial manufacturer” label implies, though Auto OEM and Construction skew toward cyclical OEM/new-build demand.

The ITW Business Model (FACT, FY25 10-K, Item 1) rests on three elements: (1) 80/20 Front-to-Back, a decades-old operating system that concentrates resources on the largest/best “80” opportunities and prunes the unprofitable “20” of customers and SKUs; (2) Customer-Back Innovation (CBI), problem-solving for “80” customers that feeds a ~21,800-patent portfolio; and (3) a decentralized, entrepreneurial culture that management explicitly calls “a defining competitive advantage.”

Verdict. A capital-light, high-margin (27% segment / 26% enterprise), well-diversified federation of niche manufacturers whose economics are far superior to the “industrial” tag — a genuine high-quality compounder, not a cyclical assembler.

3. Industry Dynamics

ITW does not operate in one industry; it operates a deliberately assembled basket of fragmented niches, and that construction is itself a structural feature — no single cycle dominates the whole.

End-market read (FACT/INTERPRETATION, FY25 10-K + Q1-26 commentary):

• Automotive OEM (~20%): Structurally the weakest. Tied to global auto build rates — a mature, cyclical, low-margin customer base under EV-transition stress. FY25 organic +2.0% vs. worldwide builds +~4%; China organic +11.8% (EV content + Chinese-OEM penetration) offset North America −2.1% and Europe −1.2%. That ITW earns 21% margins selling to an industry earning far less is evidence its content is differentiated — but it is the segment most exposed to volume cyclicality.
• Food Equipment (~17%): Attractive. Commercial foodservice equipment is replacement- and service-driven (installed base + recurring service annuity), branded, and consolidating. 27.9% margins.
• Test & Measurement and Electronics (~18%): Mixed. Electronics-production capital is cyclical (semicap/EMS swings), but a consumables/MRO tail dampens it; 24.6% margins (lowest after Auto) reflect more capital-equipment exposure.
• Welding (~12%): Attractive and high-return (32.9%). General-industrial/fabrication razor-and-blade economics with a stable global oligopoly — ITW names only Lincoln Electric and ESAB as global peers (FACT, 10-K). Cyclical but with high installed-base pull-through.
• Polymers & Fluids (~11%): Steady MRO/auto-aftermarket consumables, 27.9% margins — recession-resilient demand.
• Construction Products (~11%): Structurally cyclical and the weakest grower; revenue fell from ~$2,033M (FY23) to $1,820M (FY25) as residential construction/renovation softened under high rates. 30.2% margins show price holds even as volume contracts.
• Specialty Products (~11%): Attractive, patent-heavy niches (beverage packaging, coding/marking), 31.2% margins.

Marathon capital-cycle lens. The single most important capital-cycle fact about ITW is that its end markets are mature, fragmented, low-growth niches that are not attracting fresh capital — the opposite of the AI/data-center/electrification booms drawing capital into the Emerson/Honeywell/Ametek orbit. Mature, capital-starved, fragmented industries are precisely where Marathon’s supply-side framework predicts durable high returns persist: no greenfield capacity flooding in, incumbents disciplined, niche scale defensible (INTERPRETATION). ITW’s plateaued revenue is partly the price of that discipline — it deliberately prunes low-return volume (product-line simplification cut FY25 Auto organic by ~120 bps by design) rather than chase share at poor economics. Competitive intensity per segment is “several main competitors and numerous smaller ones” with ITW typically the niche leader (FACT, 10-K).

Verdict. Not one industry but a basket of mature, fragmented, capital-starved niches — individually average-to-good, but the portfolio construction plus supply-side discipline make the aggregate structurally attractive and unusually defensive (beta 0.71). Weakest links: Auto OEM (cyclicality) and Construction (rate-sensitivity). Structurally good — for returns; structurally low-growth for volume.

4. Competitive Position

Name the moat. In Greenwald’s taxonomy, ITW’s advantage is a combination of customer-captivity switching costs and intangibles (proprietary patented designs + brand) applied at niche scale, with the 80/20 operating system as a cost-and-execution amplifier. The mechanism: each business sells a component or consumable that is a small fraction of the customer’s total cost but critical to the customer’s product or process, designed with the customer (CBI) and protected by patents. Re-qualifying a fastener spec’d into a vehicle platform, or re-validating a welding consumable in a production line, is expensive and risky relative to the part’s trivial dollar value — so customers stay, and ITW prices disproportionately to the value delivered. This is demand-side captivity + supply intangibles, not a network effect (none exists — pressure-tested and rejected) and not enterprise-wide economies of scale (ITW is deliberately decentralized; scale lives within each niche).

Greenwald ROIC test — decisively passed, and uniquely clean. A moat must surface as ROIC durably above WACC. ITW’s ~27% ROIC (FY24 29%) and ~26% operating margins are not only well above an ~8–9% cost of capital — they are best-in-class and the cleanest in the cohort:

The decisive distinction. ITW’s 27% ROIC is fundamentally higher quality than the peer numbers because it is earned on organically built capital, not a goodwill-heavy acquisition pile. EMR, PH, ROP, AME and HON all show the same signature: strong underlying/tangible returns dragged to mediocre consolidated ROIC by serial M&A that overpaid for the capital base (both Greenwald and Marathon flag growth-by-acquisition as a routine value transfer to sellers). ITW is the rare diversified industrial whose consolidated ROIC is its elite tangible ROIC, because it grew the niche positions and refined the operating system in-house (INTERPRETATION). That is the strongest possible confirmation the moat is real and is not being quietly destroyed by capital allocation. (Note: goodwill + intangibles of ~$10.8B against ~$3.2B of book equity make tangible book negative — a function of decades of buybacks, not of overpriced M&A; see .)

Greenwald share-stability test. The 10-K describes ITW as the niche leader across “fragmented” markets. The cleanest corroboration is Welding, where ITW competes globally against only Lincoln Electric and ESAB — an oligopoly stable for decades, the hallmark of genuine entry barriers. Across segments, the 27% segment margins and through-cycle pricing power (price/cost positive even as Construction and Auto volumes fell) are strong indirect evidence of stable share — a share-loser could not hold those margins through a four-year revenue plateau and an inflation surge.

System or portfolio? (the key skeptical question.) The honest answer is both, but the durable, non-replicable part is the portfolio of niche positions; the 80/20 system is the amplifier. A culture/operating system is, in principle, replicable — Danaher (DBS), Roper and Ametek run their own decentralized acquire-and-operate playbooks. What is not easily replicable is being the entrenched, spec’d-in, patent-protected supplier of a critical-but-cheap component across 80+ niches simultaneously, each with high switching costs and a fragmented competitor set. The 80/20 system is what lets ITW monetize those positions at 27% margins; but a rival who could buy ITW’s niche positions would inherit most of the moat, whereas 80/20 applied to commodity businesses would not produce 27% margins (INTERPRETATION).

Counter-argument / weakest links. (1) Auto OEM (21% margin, ~20% of revenue) is the most cyclical and most exposed to the EV transition and OEM pricing power — its lower margin shows the moat thins where the customer is itself powerful. (2) Construction is rate-sensitive and shrinking. (3) The four-year revenue plateau is the legitimate bear point: a moat protects returns, but ITW has not converted it into organic growth — management’s own “Next Phase” strategy concedes it must “build organic growth into a core strength,” i.e., admits it has not been one. A moat without growth has limited incremental value even if it protects the existing earnings stream.

Verdict. Durable, genuine, best-in-class moat — the real article, not a narrative. ITW has the highest and cleanest ROIC in the cohort, persistent oligopoly positions, and proven through-cycle pricing power. The binding constraint on the thesis is not moat durability but the absence of organic growth.

5. Growth History and Forward Opportunities

The plateau is real and mostly structural, not franchise decay. Reported revenue has been flat-to-down for three years — $16,107M (FY23) → $15,898M (FY24) → $16,044M (FY25) — after the COVID-recovery surge ($12,574M FY20 → $14,455M FY21 → $15,932M FY22). ITW’s own organic/FX/M&A bridge (FACT, FY25 10-K MD&A):

• FY24 total −1.3% = organic −0.7%, M&A/divestiture +0.1%, FX −0.7%.
• FY25 total +0.9% = organic +0.9%, M&A/divestiture +0.1%, FX −0.8% (now reversing).
• FY23 organic was solidly positive (~+3%+) before the 2024 short-cycle/CapEx air-pocket.

So the “$16B plateau” combines (a) two years of near-zero organic volume as CapEx-exposed end markets (Test & Measurement/semis, Welding) destocked and froze capital spending, (b) a multi-year FX headwind, and © deliberate self-pruning via product-line simplification (INTERPRETATION: cyclical trough + FX + self-pruning, not erosion). ITW consistently claims 200–300 bps of market outgrowth, and segment data supports it (Auto OEM organic outgrew global builds every quarter of FY25).

Segment organic growth is bifurcated. FY25 ran from negative in consumer/construction-facing units (Construction −5.1%, Specialty roughly flat-to-negative, Auto +2%) to positive in CapEx units. The Q1-2026 print crystallizes the split: Welding +6% organic, Test & Measurement and Electronics +5% (best in three years; semi-related +15%), while Food Equipment −3% and Specialty −5% (depressed by pruning + delayed Middle East/aerospace shipments) (FACT, Q1-26 call).

The growth algorithm rests on Customer-Back Innovation. Management frames CBI as “the most impactful driver” toward a target of 4%+ high-quality organic growth. CBI contribution reached 2.4% of revenue in FY25 (+40 bps YoY), tracking toward a 3%+ by 2030 goal; the cited leading indicator (patent filings) rose 18% in FY24 and 9% in FY25 (FACT, FY25 call). INTERPRETATION: CBI is credible but unproven at scale — at 2.4% it is still ~60 bps short of the run-rate needed to deliver 4%+ enterprise organic growth without market tailwind, and management concedes it “can be lumpy.”

FY26 guidance (FACT, Q1-26 call, 2026-04-30): organic +1% to +3%, total revenue +2% to +4%, operating margin expansion ~100 bps to 26.5–27.5%, GAAP EPS $11.10–$11.50 (midpoint $11.30, +~8%) — raised $0.10 on a lower tax rate. All seven segments guided to positive organic growth and margin expansion. Order rates in Welding and T&M were described as “meaningfully higher” than Q1 organic but excluded from guidance under ITW’s conservative run-rate methodology.

Margin runway. Strategic sourcing + 80/20 front-to-back contribute ~100 bps of margin annually, largely volume-independent, and have been the primary margin driver since 2012. ITW targets a 30% operating margin by 2030 (FY25: 26.3%). Incremental margins have stepped up structurally from a historical 35–40% to a guided mid-to-high-40s, attributed to a higher-quality pruned portfolio and higher-margin new products.

Verdict. High-quality but currently slow growth. The economics are excellent (high incrementals, self-funded margin expansion, genuine market outgrowth), but the multi-year organic plateau is a legitimate concern: EPS growth has leaned on enterprise initiatives and buybacks rather than volume. The thesis hinges on whether CBI plus a CapEx-cycle recovery can re-establish 4%+ organic growth; the early-FY26 CapEx-segment acceleration is the first real evidence in three years that it might.

6. Financial Quality

Margins and returns are elite and improving. Operating margin rose from 22.9% (FY20) to a peak 26.8% (FY24) and 26.3% (FY25); gross margin ~44%; EBITDA margin ~29% (FACT, ROIC/filings). ROIC has run 24%→29%→27% (FY21–25) and ROA ~20% — exceptional for a manufacturer. The headline returns understate quality in one respect and require care in another:

• Real ROE is ~95%, not the ~10% some screens show. ITW’s stockholders’ equity is only ~$3.2B (FY25) because decades of buybacks have built $26.9B of treasury stock against $30.2B of retained earnings (FACT, FY25 balance sheet). Net income of $3.07B on ~$3.2B equity is a ~95% ROE. Screens that show ITW’s “P/B” at ~2.4x or “ROE” at ~10% are using total capital or an adjusted base; the reported book value is ~$11/share, hence the AZI P/B percentile (90th) reads high. This is a feature, not a flag — a capital-light franchise that has returned so much cash it has nearly no accounting equity left. Tangible book is negative (goodwill $5.1B + intangibles $5.7B > equity $3.2B), again a buyback artifact, not overpriced-M&A impairment risk.

Revenue: plateaued ~$16B (see ). Profit composition is clean — ITW is not manufacturing earnings through aggressive accounting.

Quality of earnings — two one-time items matter. FY24 GAAP EPS of $11.75 was flattered by ~$1.56 of non-recurring benefit: the Q3-2024 Wilsonart divestiture (sale of a noncontrolling equity interest to Clayton, Dubilier & Rice — net proceeds $395M, pre-tax gain $363M, plus a discrete tax benefit; combined ~$1.26 EPS) and a Q1-2024 LIFO accounting-method change (~$0.30, ~$117M operating-income benefit) (FACT, 8-K/10-K). Normalized FY24 EPS was therefore ~$10.19. This is why FY25 EPS of $10.52 looks down ~10% but underlying earnings actually rose ~3%. Anyone reading FY25 as an earnings decline is misreading a divestiture/tax artifact. (FY25 net income was $3,066M vs. FY24’s $3,488M; the ~$422M delta is essentially the absent Wilsonart gain and tax benefit.)

Cash flow is high-quality and conversion is strong. (FACT, ROIC/filings, $M):

FCF conversion averages ~0.9x net income (the FY22 dip was a working-capital build during the inflation/supply-chain surge, since reversed). Capex is light at ~2.6% of sales and SBC is negligible at ~0.4% of sales — a genuinely capital-light, low-dilution model, the opposite of the SBC-heavy “FCF” of many growth names.

Balance sheet — fortress. Net debt ~$8.1B against ~$4.6B EBITDA = ~1.75x net leverage; cash $851M; total debt ~$9.2B; current ratio ~1.2x (FACT, FY25 balance sheet). ITW carries A+/A2 credit ratings. Pension is small (~$205M liability). The balance sheet has ample capacity for the dividend, buyback, and opportunistic M&A simultaneously.

Verdict. Economics improve with scale and are best-in-class: 27% ROIC, ~26% margins, ~0.9x FCF conversion, near-zero SBC, fortress balance sheet, and conservative accounting. The only “quality” nuances are cosmetic (negative tangible book and ~95% ROE are both buyback artifacts) and one genuine QoE point investors must normalize for — the FY24 Wilsonart/LIFO benefit.

7. Capital Allocation

The framework is disciplined and explicitly stated (FACT, FY25 10-K): (1) internal investment for organic growth, (2) “an attractive dividend,” (3) “selective strategic acquisitions that support the Company’s organic growth focus,” and (4) “an active share repurchase program.” In practice: capex → dividend → opportunistic M&A → buy back the rest.

Cash returns are large, consistent, and shareholder-friendly (FACT, $M):

FY25 returned ~$3.3B to shareholders and raised the dividend for the 62nd consecutive year (a Dividend King), at a ~58% payout. ~$2.0B remains under the 2023 repurchase authorization. Diluted shares fell 302.6M → 296.8M → 291.5M (FY23–25) and from ~316.9M in FY20 — a steady ~1.5–2%/year reduction that management counts as ~2 pts of annual EPS growth. At a ~$76B market cap, the $1.5B/year buyback is consistent but modest in percentage terms.

M&A appetite is genuinely low — by design. Post-2012 portfolio simplification turned ITW into a buyback-first, M&A-light company. The largest recent deal was MTS Test & Simulation (~$731M, 2021); since then only small bolt-ons ($57M + $59M in 2024; $120M in Oct-2025, all in Test & Measurement). On the “renewed/expanded M&A” question, management was explicit that M&A is “on the table for the right companies” and they are “actively prospecting” and will be “appropriately aggressive,” but “the challenge is really around valuation” and “we’re not gonna do deals where we can’t generate a reasonable risk-adjusted return” (FACT, Q4-25 call). INTERPRETATION: a signal of willingness, not a strategic pivot — heavily valuation-gated, with no platform deal announced.

Incentive metrics — ROIC IS a comp metric (FACT, 2026 DEF 14A), a genuine positive versus the many industrials whose comp ignores returns:

• Annual cash bonus (EIP): 60% operating-income growth / 40% organic-revenue growth (no ROIC at the annual level).
• PSUs (3-year, cliff-vest): four equally-weighted goals — operating margin, after-tax ROIC, EPS growth, and CBI Yield (added 2025) — payout 50–200%, capped at 200%.

ROIC is thus embedded as a long-term governor, and the CBI-Yield addition aligns pay with the stated growth strategy. Say-on-pay support is strong and rising: 93.1% (2023) / 93.9% (2024) / 95.2% (2025). CEO O’Herlihy FY25 total comp was ~$15.2M.

Insider behavior is low-signal (FACT, Form 4 sweep). The corpus is overwhelmingly routine — director equity grants (code A) clustered each May and officer option-exercise/withholding/planned sales (M/F/S). The only confirmed discretionary open-market purchase was director Jennifer Scanlon (806 shares, ~$200K, 2026-06-02) — small but real. No conviction-buying cluster and no alarming discretionary selling; the tape neither confirms nor contradicts the thesis.

Verdict. Among the best capital allocators in industrials: returns-aligned long-term comp (ROIC + CBI), Dividend-King consistency, valuation-disciplined M&A restraint, and a per-share-compounding buyback. The one critique is ambition — at trough organic growth, ITW returns ~120% of FCF (dividends + buybacks ≈ $3.3B vs. $2.7B FCF, funded by balance-sheet capacity), leaving growth almost entirely dependent on internal initiatives rather than redeployment into new platforms.

8. Changes and Headwinds — Last Two Years

1. Leadership transition (FACT): Christopher O’Herlihy became CEO on 1/1/2024, succeeding E. Scott Santi (now Executive Chairman); CFO Michael Larsen is unchanged. O’Herlihy is a 30±year internal veteran — signaling strategic continuity of the 80/20/enterprise-initiatives model, not a reset. INTERPRETATION: continuity reduces execution risk but means the “fix” for slow organic growth (CBI) is incremental, not transformative. (A routine 8-K in May-2026 noted the Chief Accounting Officer will retire 3/1/2027 — not thesis-relevant.)

2. Strategy phase (FACT): ITW is in its “Next Phase (2024–2030) Enterprise Strategy,” with the headline shift being elevation of organic growth via CBI alongside the long-running margin agenda — formalized by adding CBI Yield to the PSU scorecard in 2025. The framing has tilted from “margin/returns” toward “growth + margin.”

3. The 2024 Wilsonart divestiture (FACT): completed Q3-2024, exiting a passive minority stake — consistent with portfolio simplification, and the proximate cause of FY25’s optically weak EPS comparison (the ~$1.56 one-time benefit in FY24; see ).

4. End-market headwinds, now partially abating (FACT, Q4-25/Q1-26 calls):

   • CapEx/semi-related (T&M): a 2024–25 trough (China CapEx “freeze,” semi destocking) is inflecting up — semi-related +15% organic in Q1-26, the segment’s best growth in three years.
   • Welding: multi-year weakness reversing — +6% organic in Q1-26, broad-based.
   • Consumer/Auto/Construction/Food Equipment: still soft — global auto builds ~−3%, residential construction “stuck” on high rates (a potential 2026+ upside option not in guidance).
   • FX: a multi-year drag (−0.7% to −0.8% in FY24/FY25) flipping to a Q1-26 tailwind (+3.9%).
   • Tariffs: management says direct impact is “largely mitigated” via a “produce-where-we-sell” footprint plus price recovery; price/cost guided slightly positive.

Verdict. Net mildly thesis-strengthening. The CapEx/semi and Welding inflections, the FX reversal, and the more-open-but-disciplined M&A posture are positives, layered on an unchanged high-quality model and a clean leadership transition. The offsets — persistent consumer/auto/construction softness and a still-sub-target organic algorithm — keep this from being a clear inflection. The dominant takeaway: the apparent FY25 earnings “decline” is an accounting artifact, underlying earnings power grew, and the cyclical CapEx segments are turning up for the first time in three years.

9. Risk Analysis

The dominant, intertwined risks are growth disappointment and valuation de-rating: a stock priced at the 85th percentile of its own history for a company that has not grown the top line in four years is vulnerable if the organic re-acceleration fails to materialize. The cyclical and FX risks are real but cushioned by diversification, the consumable/aftermarket tail, and a 0.71 beta. There is no plausible catastrophic-loss path.

10. Valuation Discussion (Embedded Expectations)

Where the multiple sits. At $264.09 (2026-06-18), ITW trades at ~$76B market cap / ~$84B EV, implying ~25.1x trailing FY25 EPS ($10.52), ~23.4x the FY26E midpoint ($11.30), ~18.3x EV/EBITDA, a ~3.5% FCF yield, and a ~2.3% dividend yield (FACT, computed). On ITW’s own decade-long history, the AZI valuation-percentile read places it at the 85th composite percentile (P/E 79th, P/B 91st, P/S 86th) — expensive versus its own range, but not the 95th–99th-percentile “richest-ever” extreme seen in some quality compounders (Grainger, Roper). This is a premium-but-not-euphoric multiple. Versus peers, ITW commands a deserved premium to MMM (~broken), EMR/PH (goodwill-diluted ROIC), and trades roughly in line with the highest-quality multi-industrials on EV/EBITDA, justified by its superior, cleaner ROIC.

Embedded-expectations read. A ~23x forward multiple for a company compounding EPS ~7–8% (≈ low-single-digit organic + ~1 pt margin + ~2 pts buyback + FX swing) implies the market is underwriting continuation of that algorithm with the multiple intact — i.e., the quality and the ~7–8% EPS growth are priced in, and there is modest credit for the organic re-acceleration but no demand for heroics. The market is correctly pricing ITW’s exceptional returns and capital discipline; the debatable element is whether ~23x adequately discounts the risk that organic growth stays near zero (in which case fair value is lower) or under-prices a genuine return to 4%+ organic (in which case it is cheap).

Scenario analysis (3-year horizon to ~FY28). (ASSUMPTION-driven; illustrative, not a target.)

The distribution is moderately positively skewed but anchored by a full starting multiple: the bear case is cushioned (quality + dividend ≈ no permanent loss), but the base case delivers only solid-not-spectacular returns because you start at ~23x. The asymmetry improves materially at a lower entry (~20–21x / ~$235–250), which is why the directional fair-value zone in Claude’s Take sits below today’s price. No price target is set; the above is embedded-expectations and scenario framing only.

Verdict. ITW is fairly-to-fully valued: a deserved premium multiple for a best-in-class franchise, with limited margin of safety. The market is paying for certainty of returns and getting the growth optionality cheap-ish but not free.

11. Variant Perception

Consensus view. ITW is a beloved, blue-chip quality compounder — “the best-run industrial” — that deserves its premium multiple; sell-side is broadly positive-to-neutral, valuing it on its returns and dividend reliability. The stock is held as a defensive, low-beta industrial core position.

Strongest bull case. This is a structurally superior, mis-categorized business: ~27% clean ROIC, near-zero SBC, capital-light, with a real moat (switching costs + patents at niche scale) the market under-appreciates because it is unsexy. Customer-Back Innovation is a genuine, comp-incentivized organic-growth engine just now reaching scale (2.4%→3%+), and the CapEx-cycle segments (semis +15%, Welding +6%) are inflecting up after a three-year trough with FX flipping to a tailwind. Re-establish 4%+ organic on top of self-funded margin expansion to the 30% target and buybacks, and EPS compounds at low-double-digits — at which point ~23x is cheap.

Strongest bear case. ITW is a no-growth annuity priced as a growth compounder. Revenue has been flat at ~$16B for four years; “growth” has been buybacks, margin self-help, and a one-time divestiture gain dressing up FY24. CBI has been promised for years and is still ~60 bps short of what’s needed. At ~23x forward / 85th-percentile valuation for ~0–1% organic growth, the multiple is the risk: any disappointment de-rates a fully-priced stock, and the margin-expansion runway is finite (you can only prune so much). You are paying a premium price for a business whose top line has stopped compounding.

The 3–5 assumptions that matter most:

1. Organic growth re-accelerates to ~4% (CBI to 3%+ and cyclical recovery) — the single swing factor. Falsified by: two-plus more quarters of sub-2% organic.
2. Margin expansion continues ~100 bps/year toward 30% independent of volume. Falsified by: flat/declining margins in a non-recession year.
3. The premium multiple holds (~22–24x). Falsified by: de-rating to high-teens on growth disappointment or a quality-factor unwind.
4. Capital discipline persists (no value-destructive large M&A as appetite reopens). Falsified by: an out-of-character premium-priced platform acquisition.
5. The cyclical inflection (semis/Welding) is durable, not a head-fake. Falsified by: CapEx orders rolling back over in 2H-2026.

Factor-positioning read (FactorsToday). ITW reads as an abandoned-quality / GARP-defensive name, not a crowded trade: low market beta (0.71), low idiosyncratic vol (~12%), positive loadings to Value (+0.33), DividendYield (+0.35), Quality (+0.23) and the Industrials sector (+0.44), with negative Growth (−0.18) and effectively no Momentum loading. Relative strength is modest (rs_12m +12%, ~11% off peak). Related names are other quality/dividend industrials and distributors (MSM, NDSN, AOS, PH, AIT). Interpretation: the tape is neither a momentum melt-up nor a falling knife — it is a defensive, value/quality-tilted compounder that the market has bid to a full multiple precisely because of its safety, not its growth. That supports the variant view that consensus may be slightly over-paying for certainty and under-pricing the growth optionality — the mirror image of a hyped growth name. The factor profile is evidence, not a price call.

Verdict. The most likely truth is between the camps and closer to the bear on price: a genuinely elite, durable franchise (bull is right on quality) that is fully valued for a growth re-acceleration it has not yet delivered (bear is right on price). The variant edge is recognizing that the FY24-to-FY25 “earnings decline” is an accounting illusion and that the real question — does organic growth return — is observable in the next few quarters, making this a defined “show-me” rather than an open-ended bet.

12. Fact vs. Interpretation Table

13. Open Questions

1. Can CBI actually scale to 3%+ of revenue, and is the 2.4%→ measure auditable rather than a marketing construct? What is the true incremental margin on CBI revenue?
2. Is the Q1-26 semis/Welding inflection durable into 2H-2026, or a destocking-driven head-fake? (Watch order rates vs. shipments.)
3. How much further can margins expand before the self-help (sourcing + 80/20) runway is exhausted, and what is the volume leverage if organic growth returns?
4. If M&A appetite genuinely reopens, what is the target profile — bolt-ons within segments, or a new platform — and will ITW maintain valuation discipline in a high-priced market?
5. What is normalized organic growth absent the FX and pruning noise — is the underlying franchise a ~2% or a ~4% organic grower? This is the whole thesis.
6. How exposed is Auto OEM to the EV transition on a content-per-vehicle basis over the next 5 years — net tailwind (more fasteners/assemblies) or net headwind (OEM pricing power, platform consolidation)?

14. What Must Be True

Bull case — what must be true: ITW re-establishes ~4%+ organic growth (CBI through 3% + a durable industrial/CapEx recovery), sustains ~100 bps/year margin expansion toward the 30% target, holds capital discipline, and keeps the premium multiple — compounding EPS at low-double-digits and justifying ≥23x. Falsification test: two or more additional quarters of sub-2% organic growth, or flat/declining operating margin in a non-recession year — either breaks the “re-accelerating quality compounder” thesis and exposes a no-growth annuity at a growth multiple.

Bear case — what must be true: ITW remains a ~0–2% organic grower whose EPS growth is mostly margin self-help and buybacks; the market eventually de-rates a fully-priced, slow-growth name toward high-teens, and total returns are dominated by the ~2.3% dividend. Falsification test: two or three consecutive quarters of sustained 4%+ organic growth with CBI yield through ~3% — confirming the franchise compounds on volume again, at which point the current multiple is justified-to-cheap and the bear case is wrong.

The elegant feature of ITW is that both cases are falsified by the same observable metric — organic growth over the next 2–4 quarters — making this a genuine, time-bounded “show-me” rather than an open-ended valuation debate.

15. Source Appendix

See the Source Appendix below for the full citation list. Primary sources: ITW FY2025 Form 10-K (filed 2026-02-13), FY2021–24 Form 10-Ks, FY25/FY26 Form 10-Qs, 2026 DEF 14A proxy (filed 2026-03-27), 8-K earnings releases and material-event filings (2024–26), Form 4 insider filings (2021–26), all via SEC EDGAR (CIK 0000049826). Quantitative data: ROIC.ai (financial statements, ratios, enterprise value), AZI trading (price history, valuation-percentile ranks, news), FactorsToday (factor loadings, risk metrics). Earnings-call transcripts (Q4-2025, Q1-2026) via ROIC.ai. Peer cross-reads: MMM, EMR, PH, ROP, AME, GWW, HON.

APPENDIX A — Standard Diligence Questionnaire

Illinois Tool Works Inc. (NYSE: ITW) — as of 2026-06-20

Answers grounded in public filings and data; Fact / Interpretation / Assumption labeled where it matters.

General

What thoughtful questions have other investors asked about this company? The recurring institutional debates: (1) Is ITW a growth business or a no-growth annuity — can it ever re-accelerate organic growth above ~2%? (2) Is the 80/20 operating system a durable, non-replicable moat, or a culture other decentralized operators (Danaher, Roper, Ametek) have copied? (3) Is the margin-expansion runway (~100 bps/year toward a 30% target) finite, and what happens to EPS growth when it runs out? (4) Why does ITW return ~120% of FCF to shareholders rather than redeploy into higher-growth M&A — is that discipline or a lack of opportunity? (5) Does the premium ~23x multiple adequately compensate for ~0% top-line growth?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? (Interpretation) Mixed-to-mid-cycle, tilted toward a trough in the CapEx-exposed segments. Test & Measurement (semis) and Welding came off a 2024–25 cyclical low and were inflecting up in Q1-26 (semis +15%, Welding +6% organic). Consumer/auto/construction-facing segments remain soft. Aggregate organic growth (+0.9% FY25) is below trend, suggesting earnings are not at a cyclical high. Margins, however, are near record highs (26.3%).

Driven by external environment or internal actions? Both. ~100 bps/year of margin expansion is internally driven (strategic sourcing + 80/20), largely volume-independent. Top-line growth is externally constrained (industrial/auto/construction cycle, FX). EPS growth has lately come more from internal levers (margin + buyback) than external demand.

How stable are revenues? Very stable in aggregate (~$16B ± 1% for four years) but with offsetting segment cyclicality; the consumable/aftermarket/service tail (Welding consumables, Food Equipment service, Polymers/Specialty consumables) dampens swings. Beta 0.71.

Outlook for products/services? Mature, low-growth niches with steady replacement/consumable demand; new growth dependent on Customer-Back Innovation and a CapEx-cycle recovery.

How big will this market be — growing, shrinking, domestic or international? ITW’s served niches are mature, low-single-digit-growth markets; ~47% of revenue is international. The addressable market is not shrinking but is not a structural grower — ITW’s growth must come from market outgrowth (CBI) rather than market expansion.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Roughly stable; ITW’s niches are fragmented with stable competitor sets (Welding is a clear oligopoly with Lincoln Electric and ESAB). No evidence of intensifying competition eroding returns.

How profitable is the business (ROIC, ROE)? Elite: ROIC ~27% (FY24 29%), real ROE ~95% (on ~$3.2B equity after $26.9B treasury stock), operating margin ~26%, gross margin ~44%. (Fact)

How profitable is the industry — competitors, barriers to entry? ITW out-earns its industries (e.g., 21% margins selling to low-margin auto OEMs), evidence of differentiated, spec’d-in content. Barriers: switching costs (re-qualification risk on critical-but-cheap components), patents (~21,800), niche scale. Peers earn high tangible returns but lower consolidated ROIC due to goodwill-heavy M&A.

Can the business be easily understood? Yes at the model level (decentralized niche manufacturer on an 80/20 system), though the 80–90 underlying businesses are individually opaque.

Can it be undermined by foreign low-cost labor? Limited risk — products are engineered, patent-protected, and a small fraction of customer cost; ITW produces regionally (“produce-where-we-sell”). Commodity exposure is low.

Do brands matter? Selectively — in Welding (Miller), Food Equipment (Hobart), and Construction, brand + installed base matter; elsewhere the moat is switching costs/patents more than consumer brand.

Nature of competition? Fragmented niche competition; ITW typically the leader, competing on engineering/problem-solving and service, not price.

Customers’ switching costs? High relative to the part’s cost — re-qualifying a component spec’d into a vehicle platform or production line is expensive and risky. This is the core of the moat.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The ~21,800-patent portfolio and the 80/20 operating system / decentralized culture are valuable intangibles carried at little/no book value. Negative tangible book is a buyback artifact, not asset weakness.

Off-balance-sheet liabilities? Nothing material flagged; small pension liability (~$205M). Operating leases capitalized. Conservative accounting.

How conservative is the accounting? Conservative — LIFO inventory (the 2024 LIFO method change was a rare adjustment), negligible SBC (~0.4% of sales), clean FCF conversion (~0.9x NI). The one QoE item to normalize is the FY24 Wilsonart gain + LIFO benefit (~$1.56 EPS).

How capex-hungry is the business? Light — capex ~2.6% of sales (~$419M FY25). A genuinely capital-light compounder.

Capital Allocation & Management

How much FCF, and how is it used? ~$2.7B FY25 FCF. Waterfall: capex → dividend (~$1.79B, 62nd consecutive annual increase, ~58% payout) → opportunistic M&A → buybacks (~$1.5B/yr). Returns ~120% of FCF to shareholders.

Significant acquisitions recently? Minimal — MTS Test & Simulation (~$731M, 2021) was the last sizeable deal; only small bolt-ons since ($57M/$59M 2024, $120M Oct-2025). Management signals renewed willingness but remains valuation-gated.

Buying back shares? Yes — steady ~$1.5B/yr, ~1.5–2%/yr share-count reduction; ~$2.0B remaining authorization.

Issuing large amounts of stock to insiders? No — SBC is negligible (~0.4% of sales); dilution is minimal.

Compensation policy / incentive alignment? Above-average: annual bonus on operating-income growth (60%) + organic-revenue growth (40%); long-term PSUs on four equal goals including after-tax ROIC and CBI Yield. Say-on-pay 95.2% (2025). CEO O’Herlihy ~$15.2M FY25.

Motivations of management? Continuity-minded internal veterans (O’Herlihy CEO since 1/1/2024) executing the established enterprise model; comp aligned to returns and the growth strategy.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — ordinary US common stock (NYSE: ITW); standard 1099 dividend.

Dividend policy? Dividend King — 62 consecutive annual increases; ~58% payout target; ~2.3% current yield; FY25 div/share ~$6.12.

How profitable is the business? Among the most profitable diversified industrials (see ROIC/margins above).

Is net income diverging from cash from operations? No material divergence — FCF/NI ~0.9x over five years (FY22 dip was a working-capital build during the inflation surge, since reversed).

Risks & Downside

What would cause the stock to decline? Organic growth re-stalling toward zero; multiple de-rating from the 85th-percentile starting point; an industrial/auto/construction downturn; a value-destructive large acquisition; or a quality-factor unwind.

Risk of catastrophic loss? Very low — diversified, profitable, fortress balance sheet (1.75x net leverage, A+/A2), hard assets, 62-year dividend.

Chance of total loss? Negligible.

Recent News & Events

Has the business environment changed recently? Yes, modestly positive: CapEx-exposed segments (semis, Welding) inflecting up after a 3-year trough; FX flipping from headwind to tailwind (+3.9% Q1-26); FY26 guide for margin expansion and ~8% EPS growth.

Significant acquisitions? Only small bolt-ons; renewed-but-disciplined M&A signaling.

Change in accounting policies? Q1-2024 LIFO method change (~$0.30 EPS benefit); otherwise stable.

Recent changes — markets, facilities, management? CEO transition (O’Herlihy, 1/1/2024); “Next Phase (2024–2030)” strategy elevating organic growth via CBI; 2024 Wilsonart divestiture; CAO retirement announced for 3/1/2027 (immaterial).

APPENDIX B — Source Appendix

Illinois Tool Works Inc. (NYSE: ITW) — research as of 2026-06-20

Primary sources first. All SEC filings via EDGAR, CIK 0000049826. Quantitative figures reconciled to filings where material; third-party aggregators (ROIC.ai, AZI, FactorsToday) used for ratios, prices, valuation percentiles, and factor data and labeled as such.

Primary — SEC filings (EDGAR, CIK 0000049826)

Primary — earnings-call transcripts

Quantitative / third-party data

Peer / cross-read

Public peer comparables (MMM, EMR, PH, ROP, AME, GWW, and HON) were referenced for peer ROIC/margin/multiple comparison and diversified-industrial industry framing.

Key computed figures (as of 2026-06-18 close, $264.09)

• Market cap ~$76.2B; enterprise value ~$84.3B (net debt ~$8.1B)
• P/E ~25.1x trailing (FY25 EPS $10.52) / ~23.4x FY26E ($11.30 midpoint)
• EV/EBITDA ~18.3x (FY25 EBITDA ~$4.61B); FCF yield ~3.5%; dividend yield ~2.3%
• ROIC ~27% (FY25), ~29% (FY24); operating margin 26.3%; gross margin 44.1%
• Net leverage ~1.75x; capex ~2.6% of sales; SBC ~0.4% of sales